Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 128

1.

The Effects of Systemic Alfuzosin and Tamsulosin Hydrochloride on Choroidal Thickness and Pupil Diameter Sizes in Cases with Benign Prostatic Hyperplasia.

Dogan M, Kutluksaman B, Keles I, Karalar M, Halat AO.

Curr Eye Res. 2017 Dec;42(12):1638-1643. doi: 10.1080/02713683.2017.1359306. Epub 2017 Sep 22.

PMID:
28937828
2.

Prophylactic effects of alpha-blockers, Tamsulosin and Alfuzosin, on postoperative urinary retention in male patients undergoing urologic surgery under spinal anaesthesia.

Akkoc A, Aydin C, Topaktas R, Kartalmis M, Altin S, Isen K, Metin A.

Int Braz J Urol. 2016 May-Jun;42(3):578-84. doi: 10.1590/S1677-5538.IBJU.2015.0256.

3.

A randomized, comparative, open-label study of efficacy and tolerability of alfuzosin, tamsulosin and silodosin in benign prostatic hyperplasia.

Manjunatha R, Pundarikaksha HP, Madhusudhana HR, Amarkumar J, Hanumantharaju BK.

Indian J Pharmacol. 2016 Mar-Apr;48(2):134-40. doi: 10.4103/0253-7613.178825.

4.

Decreased urinary glycosaminoglycan excretion following alfuzosin treatment on ureteral stent-related symptoms: a prospective, randomized, placebo-controlled study.

Liu S, Yu Y, Gao Y, Yang X, Pang Z.

Urolithiasis. 2016 Apr;44(2):185-90. doi: 10.1007/s00240-015-0810-4. Epub 2015 Aug 5.

PMID:
26242466
5.

Alfuzosin treatment improves the rate and time for stone expulsion in patients with distal uretral stones: a prospective randomized controlled study.

El Said NO, El Wakeel L, Kamal KM, Morad Ael R.

Pharmacotherapy. 2015 May;35(5):470-6. doi: 10.1002/phar.1593.

PMID:
26011140
6.

Multicenter, prospective, comparative cohort study evaluating the efficacy and safety of alfuzosin 10 mg with regard to blood pressure in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia with or without antihypertensive medications.

Zhang LT, Lee SW, Park K, Chung WS, Kim SW, Hyun JS, Moon DG, Yang SK, Ryu JK, Yang DY, Moon KH, Min KS, Park JK.

Clin Interv Aging. 2015 Jan 17;10:277-86. doi: 10.2147/CIA.S74102. eCollection 2015.

7.

Long term effectiveness on prescribing of two multifaceted educational interventions: results of two large scale randomized cluster trials.

Magrini N, Formoso G, Capelli O, Maestri E, Nonino F, Paltrinieri B, Del Giovane C, Voci C, Magnano L, Daya L, Marata AM; INDRA-NET study group.

PLoS One. 2014 Oct 17;9(10):e109915. doi: 10.1371/journal.pone.0109915. eCollection 2014.

9.

The effects of tamsulosin and alfuzosin on iris morphology: an ultrasound biomicroscopic comparison.

Aktas Z, Yuksel N, Ceylan G, Polat F, Hasanreisoglu M, Hasanreisoglu B.

Cutan Ocul Toxicol. 2015 Mar;34(1):38-41. doi: 10.3109/15569527.2014.903262. Epub 2014 Apr 14.

PMID:
24730669
10.

Comparison of alfuzosin 10 mg with or without propiverine 10 mg, 20 mg in men with lower urinary tract symptom and an overactive bladder: randomised, single-blind, prospective study.

Cho HJ, Shin SC, Seo DY, Cho JM, Kang JY, Yoo TK, Yu JH, Sung LH, Moon HS.

Int J Clin Pract. 2014 Apr;68(4):471-7. doi: 10.1111/ijcp.12339. Epub 2014 Jan 29.

PMID:
24471868
11.

Prospective masked comparison of intraoperative floppy iris syndrome severity with tamsulosin versus alfuzosin.

Chang DF, Campbell JR, Colin J, Schweitzer C; Study Surgeon Group.

Ophthalmology. 2014 Apr;121(4):829-34. doi: 10.1016/j.ophtha.2013.10.031. Epub 2013 Dec 4.

PMID:
24314842
12.

Role of α-blockers in the treatment of stent-related symptoms: a prospective randomized control study.

Dellis AE, Keeley FX Jr, Manolas V, Skolarikos AA.

Urology. 2014 Jan;83(1):56-61. doi: 10.1016/j.urology.2013.08.067. Epub 2013 Nov 6.

PMID:
24210570
13.

A comparative study on the use of tamsulosin versus alfuzosin in spontaneous micturition recovery after transurethral catheter removal in patients with benign prostatic growth.

Maldonado-Ávila M, Manzanilla-García HA, Sierra-Ramírez JA, Carrillo-Ruiz JD, González-Valle JC, Rosas-Nava E, Guzman-Esquivel J, Labra-Salgado IR.

Int Urol Nephrol. 2014 Apr;46(4):687-90. doi: 10.1007/s11255-013-0515-y. Epub 2013 Sep 24.

PMID:
24061764
14.

[The evaluation of efficacy and safety of treatment with dalfaz SR in patients with prostatic adenoma].

Rasner PI, Pushkar' DIu.

Urologiia. 2013 May-Jun;(3):34-6, 38. Russian.

PMID:
23987046
15.

Evaluation of patient outcome after discontinuation of alfuzosin treatment for benign prostatic hyperplasia: a multicentre, prospective study.

Chung JH, Lee JY, Kang DH, Jo JK, Lee JW, Lee SH, Lee KS, Kim TH, Han JH, Lee SW.

Int J Clin Pract. 2013 Sep;67(9):870-5. doi: 10.1111/ijcp.12108.

PMID:
23952466
16.

Combining benefits of an adrenergic and a muscarinic blocker in a single formulation - a pharmacokinetic evaluation.

Nazarudheen S, Dey S, Kandhwal K, Arora R, Reyar S, Khuroo AH, Monif T, Madan S, Arora V.

Regul Toxicol Pharmacol. 2013 Nov;67(2):226-31. doi: 10.1016/j.yrtph.2013.07.015. Epub 2013 Aug 7.

PMID:
23933032
17.

Alpha-blockers impact stent-related symptoms: a randomized, double-blind, placebo-controlled trial.

Nazim SM, Ather MH.

J Endourol. 2012 Sep;26(9):1237-41. doi: 10.1089/end.2012.0036. Epub 2012 Jun 25.

PMID:
22563773
18.

Efficacy of alfuzosin and sildenafil combination in male patients with lower urinary tract symptoms.

Öztürk Mİ, Kalkan S, Koca O, Güneş M, Akyüz M, Karaman MI.

Andrologia. 2012 May;44 Suppl 1:791-5. doi: 10.1111/j.1439-0272.2011.01268.x. Epub 2011 Dec 23.

PMID:
22211956
19.

Treatment with a uroselective α1-blocker improves voiding and sexual function: a study in Thai men with lower urinary tract symptoms.

Permpongkosol S, Krilad-O-Larn S, Ratana-O-Larn K.

J Sex Med. 2011 Sep;8(9):2582-9. doi: 10.1111/j.1743-6109.2011.02359.x. Epub 2011 Jun 23.

PMID:
21699664
20.

Medical expulsive therapy using alfuzosin for patient presenting with ureteral stone less than 10mm: a prospective randomized controlled trial.

Chau LH, Tai DC, Fung BT, Li JC, Fan CW, Li MK.

Int J Urol. 2011 Jul;18(7):510-4. doi: 10.1111/j.1442-2042.2011.02780.x. Epub 2011 May 18.

Supplemental Content

Loading ...
Support Center